April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Multifocal Pupillography Identifies Ranibizumab Induced Changes In Retinal Function For Exudative Age-related Macular Degeneration
Author Affiliations & Notes
  • Faran Sabeti
    Vision Science, Australian National University, Canberra, Australia
  • Ted Maddess
    Vision Science, Australian National University, Canberra, Australia
  • Rohan W. Essex
    Ophthalmology, Canberra Hospital, Canberra, Australia
  • Andrew James
    Vision Science, Australian National University, Canberra, Australia
  • Footnotes
    Commercial Relationships  Faran Sabeti, Seeing Machines (R); Ted Maddess, Seeing Machines (F, I, C, P, R); Rohan W. Essex, None; Andrew James, Seeing Machines (I, F, C, P, R)
  • Footnotes
    Support  Australian Research Council through the ARC Centre of Excellence in Vision Science (CE0561903)
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3890. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Faran Sabeti, Ted Maddess, Rohan W. Essex, Andrew James; Multifocal Pupillography Identifies Ranibizumab Induced Changes In Retinal Function For Exudative Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3890.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To investigate the efficacy of intravitreal ranibizumab injection for choroidal neovascularization (CNV) secondary to exudative Age-related Macular Degeneration (AMD) by evaluation of multifocal pupillographic objective perimetry (mfPOP).

 
Methods:
 

Pupil responses from 20 exudative AMD patients treated unilaterally with intravitreal ranibizumab were recorded before treatment and after 3 months treatment and compared with 30 normal subjects. Two multifocal stimulus ensembles consisting of 44 or 24 independent stimulus regions per eye with a mean presentation interval at each region of 1 second was presented dichoptically. Pupil responses were recorded with video cameras under infrared illumination. The stimulus layout extended from fixation to 15º eccentricity and presented stimuli at a luminance of 250 cd/m² and a background of 10 cd/m². A multivariate linear model was fitted to contraction amplitudes and time to peak responses to determine the independent effects of exudative AMD at pre and post-treatment.

 
Results:
 

Mean additional response delays for the 24 region stimulus improved significantly from a mean delay of 18.82 ± 3.0 ms (P < 0.0001) at baseline to 6.47 ± 3.13 ms (P < 0.05) after 3 months treatment. The mean effect of exudative AMD at baseline decreased constriction amplitudes by 1.3 times (-1.00 ± 0.23 µm, P < 0.0001). After 3 months of treatment exudative AMD produced smaller responses than normals by a multiplicative loss of 1.15 times (-0.63 ± 0.17 µm, P < 0.0005). Diagnostic performance was greater at baseline achieving an ROC area under the curve (AUC) of 100% ± 0.0 (mean ± SE) than at post-treatment (96.1% ± 3.8%).

 
Conclusions:
 

This study demonstrates the ability of mfPOP to detect functional improvements in eyes treated with intravitreal ranibizumab for exudative AMD and may assist in detecting progression or monitoring the effect of treatment. The 44 region stimulus ensemble demonstrated greater sensitivity for the diagnosis of exudative AMD at baseline than at post-treatment examination.

 
Keywords: pupil • age-related macular degeneration • perimetry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×